AllianceBernstein’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

AllianceBernstein’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-310,218	Closed	-$14.9M	–	3335
2020 Q1	$14.9M	Sell	310,218 -198,791	-39%	-$9.25M	0.01%	782
2019 Q4	$23.9M	Sell	509,009 -265,636	-34%	-$11.7M	0.01%	764
2019 Q3	$18.3M	Buy	774,645 +735,145	+1,861%	+$21.8M	0.01%	827
2019 Q2	$1.19M	Buy	39,500 +12,900	+48%	+$295K	﹤0.01%	2234
2019 Q1	$596K	Buy	26,600 +1,300	+5%	+$27.9K	﹤0.01%	2457
2018 Q4	$460K	Buy	25,300 +7,900	+45%	+$124K	﹤0.01%	2518
2018 Q3	$315K	Buy	17,400 +2,700	+18%	+$32K	﹤0.01%	2829
2018 Q2	$146K	Buy	+14,700	New	+$101K	﹤0.01%	3020
2017 Q3	–	Sell	-10,400	Closed	-$195K	–	3145
2017 Q2	$195K	Buy	+10,400	New	+$235K	﹤0.01%	2999

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

AllianceBernstein's RARX Position: Q2 2020 in Review

AllianceBernstein sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 310,218 shares — an estimated $14.9M sold.

AllianceBernstein first reported a position in RARX in Q2 2017 and held it in 9 quarters. The position peaked at $23.9M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

AllianceBernstein reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
AllianceBernstein sold 310,218 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $14.9M.
AllianceBernstein first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 9 quarters.
AllianceBernstein's Ra Pharmaceuticals, Inc. Common Stock position peaked at $23.9M in Q4 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on AllianceBernstein's 13F filing for Q2 2020, filed 13 Aug 2020.